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Abstract 
Serum uric acid level above 7 mg/dl is defined as hyperuricemia, which gives rise to 
the monosodium urate (MSU), causing gout and urolithiasis. Hyperuricemia is an 
independent risk factor as well as a marker for hypertension, heart failure, 
atherosclerosis, atrial fibrillation and chronic kidney disease. MSU crystals, soluble 
uric acid (UA) or oxidative stress derived from xanthine oxidoreductase (XOR) might 
be plausible explanations for the association of cardio-renovascular diseases with 
hyperuricemia. In macrophages, MSU activates the Nod-like receptor family, pyrin 
domain containing 3 (NLRP3) inflammasome and proteolytic processing mediated by 
caspase-1 with enhanced interleukin (IL)-1β and IL-18 secretion. Soluble UA 
accumulates intracellularly through UA transporters (UAT) in vascular and atrial 
myocytes, causing endothelial dysfunction ad atrial electrical remodeling. XOR 
generates reactive oxygen species (ROS) that lead to cardiovascular diseases. Since it 
remains unclear whether asymptomatic hyperuricemia could be a risk factor for 
cardiovascular and kidney diseases, European and American guidelines do not 
recommend pharmacological treatment for asymptomatic patients with cardio-
renovascular diseases. The Japanese guideline, on the contrary, recommends 
pharmacological treatment for hyperuricemia with CKD to protect renal function, and 
it attaches importance of the cardio-renal interaction for treatment of asymptomatic 
hyperuricemia patients with hypertension and heart failure. In this review, the authors 
report the associations of hyperuricemia with cardiovascular diseases, and discuss its 
underlying mechanisms and the clinical implication of Japanese guideline 3rd edition 
of management for hyperuricemia and gout. 
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INTRODUCTION 
  Hyperuricemia occurs in 20 % of men and in 5 % of 
women in the entire Japanese population.1 Gene 
mutations may accelerate uric acid production or reduce 
either renal or extrarenal excretion of uric acid.1 In 
addition, a diverse range of environmental factors causes 
hyperuricemia. Hyperuricemia is defined as the serum 
urate level above 7.0 mg/dl.1 Hyperuricemia increases the 
uric acid pool to give rise to MSU crystals, which causes 
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 While clinical studies suggested that asymptomatic 
hyperuricemia frequently associates with cardiovascular 
diseases, it remains unclear whether hyperuricemia 
could be a risk factor for cardiovascular diseases (CVD), 
hypertension, stroke, atrial fibrillation (AF), metabolic 
syndrome (Mets), nonalcoholic fatty liver disease 
(NAFLD), chronic kidney disease (CKD) and diabetes 
mellitus (DM) (Table 1). The underlying mechanisms on 
the associations of hyperuricemia with cardiovascular 
diseases and the clinical implication of Japanese 
guideline 3rd edition of management for hyperuricemia 
and gout1 have been discussed. 
 
Formation and physical properties of uric acid and 
the definition of hyperuricemia  
1) Formation of uric acid 
 Since evolutionally loss of uricase activity, uric acid 
has been the end product of purine metabolism in the 
human body. Uric acid is synthesized from xanthine by 
xanthine oxidoreductase as well as from guanosine. The 
free purine bases, yielded by nucleoside cleavage are 
adenine, guanine, hypoxanthine and xanthine. Since 
purine nucleoside phosphorylase acts with relatively 
higher affinity on inosine and guanosine, the major bases 
generated are hypoxanthine and guanine. Hypoxanthine 
is oxidized to xanthine by xanthine oxidoreductase 
(XOR) and then further oxidized to uric acid by the same 
enzyme, while guanine is oxidized to xanthine. Uric acid 
synthesis happens mainly in the liver, where XOR is 
richly expressed.2 
 
2) Solubility of uric acid in plasma 
 The weak acidity of uric acid is due to ionization of 
hydrogen atoms at positions 9 (pKa=5.75) and 3 
(pKa=10.3). The ionized forms of uric acid easily form 
monosodium urate (MSU), and at pH7.4, approximately 
98% of uric acid takes this form. When the concentration 
of MSU exceeds the solubility limit of body fluid, the 
crystals as monosodium urate monohydrate are formed 
in the synovial fluid or the tophi. Based on the MSU 
solubility product is 4.9×10-5, aqueous solution with the 
sodium concentration under physiological conditions is 
saturated with MSU at 6.4 mg/dl at 37℃. MSU 
solubility in the presence of 140 mM Na+ depends on 
temperature and is saturated with 6.8mg/dl at 37℃. 
Solubility of uric acid and MSU also depends on pH: 
with increasing pH uric acid is more soluble, whereas 
MSU is less. Seegmiller et al reported that when MSU 
crystal was incubated with serum obtained from gouty or 
nongouty subjects at 38℃, actual determination MSU in 
human plasma indicated that saturation occurs at about 
7mg/dl. Considerably higher concentrations of MSU in 
plasma above 7 mg/dl can be achieved in a 
supersaturated solution, since serum contains factors that 
enhance urate solubility such as proteins. However, 
these solutions are unstable and MSU readily 
precipitates out. Thus, based on the solubility of MSU in 
plasma, hyperuricemia is defined as the serum urate 
level above 7mg/dl.1 
 
3) Crystalline Forms 
 Hyperuricemia was previously categorized to three 
types; the urate over-production type, the urate 
underexcretion type and the mixed types. Recently, the 
reduced urate extrarenal excretion type due to impaired 
uric acid secretion transporter, ABCG2 has been added.1 
SUA level above 7mg/dl increases the frequency of gout 
arthritis. MSU occurs as monohydrate and forms crystals 
that are needle- or bar-shaped in a monoclinic or triclinic 
system. When rapidly crystalized in a pure solution, 
crystals are very fine and appear amorphous. Tissue 
deposits are composed of MSU monohydrate, while 
urinary stones are composed largely of uric acid. Both 
urate and uric acid crystals show strong negative 
birefringence when viewed under polarized light.3 MSU 
crystals are taken up by macrophages in the joint. In these 
cells, the assembly of the NLRP3 inflammasome 
activates caspase-1, leading to production of IL-1  and 
IL-18.  
 
Evidence for the role of hyperuricemia and gout as a 
risk factor for cardio-renovascular diseases  
1) Uric Acid and Hypertension 
 Hyperuricemia is a common complication of 
hypertension. 17 to 25% of hypertensive patients have 
hyperuricemia and this ratio increases to 65–75% in those 
with untreated hypertension.4 Decreased renal blood 
flow5 and tubular secretion of uric acid6 have been 
reported to cause hyperuricemia in hypertension. 
Hyperinsulinemia secondary to insulin resistance has 
also been reported to contribute to its association with 
hypertension via enhancing renal reabsorption of uric 
acid through URAT1. Enhanced myogenic production of 
uric acid precursor hypxanthine is associated with 
elevation of SUA level in untreated hypertension.7 
 Uric acid could be a risk factor for hypertension. 
Kuwabara et al8 reported that the occurrence of 
hypertension in hyperuricemic patients was 1.5 times 
higher than that in normouricemic patients. A meta-
analysis on 18 cohort studies revealed the relative risk for 
hypertension of 1.41 (Table 1). Uric acid lowering agents 
might reduce blood pressure in certain hypertensive 
patients. Administration of allopurinol or probenecid 
reduced the SUA and this decrease was accompanied by 
reduction of blood pressure in adolescent male 
prehypertension subjects. A meta-analysis using 
interventional studies indicated that allopurinol reduced 
systolic blood pressure by 3.3 mmHg and diastolic blood 
pressure by 1.3 mmHg.9 Taken together, hyperuricemia 
could not only be a marker but also a risk factor for 
hypertension. 
2) Uric Acid and Heart Failure 
 Hyperuricemia is often accompanied by heart failure 
(HF), since 47-56% of patietns with heart failure has been 
reported to associate with hyperuricemia10,11. In patients 
with HF, the prevalence of hyperuricemia ranges from 30 
to 60%.12 Incidence of heart failure was ≈6-fold higher in 
patients with the highest quartile of serum uric acid (>6.3 
mg/dL) than incidence in those with the lowest quartile 
(<3.4 mg/dL). Adjusted hazard ratio for the highest 
quartile of serum uric acid compared with the lowest was 
2.1 (1.04 to 4.22). Ogino et al11 reported that the 
prevalence of hyperuricemia increased in line with the 
NYHA classification and that the level of serum uric acid 
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Mortality of patients with HF depends on the level of 
SUA. Hyperuricemia was also an indicator of poor 
prognosis in HF.13 A meta-analysis of observational 
studies showed that hyperuricemia was associated with 
an increased risk of HF and the risk of all-cause mortality 
and the composite endpoint, respectively.14  
 Several studies asked whether uric acid lowering 
agents could influence the prognosis of HF. In meta-
analysis of 5 case-controlled studies, uric acid lowering 
agents reduced cardiovascular mortality in patients with 
heart failure. There were two reports of randomized 
control trials in patients with chronic HF treated with 
xanthine oxidase inhibitors. In OPT-CHF study,15 
oxipurinolol did not influence the composite primary 
endo points in patients with HF. In EACT-HF study,16 
which examined whether allopurinol suppresses the 
cardiovascular mortality of patients with HF whose SUA 
>9.5mg/dl, there was no difference either in 
cardiovascular mortality or re-hospitalization between 
allopurinol and placebo group. Taken together, 
hyperuricemia is a marker of HF, but it remains 
unelucidated whether hyperuricemia is a risk factor for 
HF. 
 
3) Uric acid and renal disease 
 Hyperuricemina is recognized as a risk of CKD as 
shown in meta-analysis (Table 1). A meta-analysis,1 
with 255 patients in the drug intervention group and 239 
subjects in the control group, showed a statistically 
significant difference in the amount of change 
determined as 4.12 mL/min/1.73 m2. A meta-analysis, 
with 134 patients in the drug intervention group and 106 
subjects in the control group,1 revealed a risk ratio on the 
onset of renal events of 0.51, indicating a statistically 
significant difference between groups. Taken together, 
hyperuricemia is an independent risk factor for CKD. 
 
4) Uric acid and atherosclerosis  
 Because of oxidative stress induced by SUA, 
hyperuricemia is associated with endothelial dysfunction 
and atherosclerosis. Flow-mediated vasodilation (FMD), 
an index of endothelial function, was impaired in 
patients with hyperuricemia.17 Since activation of XOR 
would increase both SUA and ROS, XOR inhibitors 
could be beneficial to prevent endothelial dysfunction. 
According to a double-blind study, allopurinol improved 
endothelial function measured by the forearm blood flow 
response to acetylcholine, in subjects with chronic HF.18   
 Incidence of hyperuricemia in patients with 
myocardial infarction is 48%.19 Three meta-analyses 
indicated that high SUA increased the risk of MI (RR: 
1.20) and mortality (RR: 1.22).20 A meta-analysis 
enrolling 8776 patients with acute coronary syndrome 
(ACS) showed that higher SUA level increased the risk 
of MACE (RR: 1.86), all-cause mortality (RR: 1.86) and 
cardiovascular mortality (RR: 1.74).21 As shown in Table 
1, the relative risks of morbidity and mortality of 
ischemic heart disease were reported to be 1.09 and 1.16, 
respectively, in patients with hyperuricemia. Urate-
lowering have been shown to reduce the risk of MI.22 
Taken together, hyperuricemia is a predictor of 
atherosclerosis and may be a risk factor for ischemic 
heart disease. 
 
5) Uric acid and atrial fibrillation  
 Prevalence of hyperuricemia in patients with atrial 
fibrillation (AF) was higher (2.1%) than in those without 
hyperuricemia (1.7%). Incidence of AF in patients with 
gout increased with hazard ratio of 1.61 and the estimated 
prevalence was 7.42%.23 A follow up for 9 years of SUA 
in 107,360 Chinese patients revealed that the highest 
quartile of SUA had 1.91 times higher risk of AF in 
comparison to the lowest quartile.24 Incidence of AF with 
elevated SUA correlates linearly with age (OR: 2.08).25 
A cohort study in Korea enrolling 282,473 patients 
indicated that the risk of AF in woman was 6.93-fold 
higher in the highest quartile of SUA than the lowest 
quartile, although in the men it was higher in the third and 
the highest quartile with hazard ratio 1.53 and 1.60 
respectively.26 In Japanese patients with hyperuricemia 
had an increased risk to develop AF (OR: 3.187).27 
Similarly (Table 1), SUA ≥6.5 mg/dl in men and SUA ≥ 
4.9 mg/dl in women induced AF with hazard ratio of 1.60 
and 1.64, respectively.28 Meta-analysis revealed that the 
relative risk of AF in patients with high SUA was 1.67.29 
Data from another meta-analysis indicated that in 
hyperuricemia patients the risk of new onset or 
recurrence of AF was 1.66 and 2.07, respectively.30 
Reduction of SUA with a use of urate-lowering therapy 
reduced incidence of AF (HR: 0.65).31 Taken together, 








Onset on CKD 15 99205 1.22 PLoS One 9:3100801,2014 
Onset on hypertension 18 55607 1.41 Arthritis Care Res 63:102-110, 2011 
Coronary events 13 69898 1.09 Arthritis Care Res 62:170-180, 2010 
Coronary death 13 333099 1.16 Arthritis Care Res 62:170-180, 2010 
Onset on stroke 16 222099 1.47 Arthritis Reum 61:885-891, 2009 
Stroke death 16 238449 1.26 Arthritis Reum 61:885-891, 2009 
Onset on AF 7 146792 1.8 Int J cardiol 184: 699-702, 2015 
Onset on Mets 9 51249 1.3 J Clin Endocrinol Metab 100: 4198-4207, 2015 
Onset on NAFLD 9 51249 1.21 J Clin Endocrinol Metab 100: 4198-4207, 2015 
Onset on DM 7 32016 1.56 PLoS One 8:e56864,2013 
 
CKD: chronic kidney disease, AF: atrial fibrillation, Mets: metabolic syndrome, NAFLD: nonalcoholic fatty liver disease, 
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Figure 1. Activation of NLRP3-inflammasome by MSU 
crystal 
After priming through activation of toll-like receptor (TRL), 
which produces pro-IL-1beta and pro-IL-18, MSU crystal 
absorbed in macrophage activates NLRP3-inflammasome via 
either K+ efflux, ROS or lysosomal damage, leading to process 
caspase1, which cleavages pro-IL-1beta and pro-IL-18 to 
produce IL-1beta and IL-18 
 
Mechanisms Underlying Cardiovascular Risk Due to 
MSU Crystals, Soluble Uric Acid and Xanthine 
Oxidase  
 
1) Monosodium Urate and Cardiovascular Diseases 
 Inflammation underlies various diseases such as 
rheumatic, gout and cardiovascular diseases. 
Hyperuricemia causes nucleation of monosodium urate 
(MSU) crystals, causing gout. The inflammatory 
response due to MSU crystals is affected by their size, 
electrostatic charge, state of aggregation and the presence 
and nature of coating proteins.2 MSU crystals are taken 
up by macrophages. In these cells, assembly of the 
NLRP3 inflammasome activates caspase-1 (Figure 1). 
Caspase-1 cleaves pro-IL-1β leading to secretion of 
active IL-1β.32,33 NLRP3 inflammasome may play a 
pivotal role in the onset of not only gout but also various 
diseases such as chronic kidney disease, cardiovascular 
disease, atrial fibrillation, metabolic syndrome and 
diabetic complications.34  
Figure 2. Intracellular uric acid and xanthine oxidase 
induces endothelial dysfunction 
Through converting from hypoxanthine to xanthine and uric 
acid, XOR (xanthine oxidoreductase) generate free radical, 
causing endothelial dysfunction. Soluble uric acid via a uric 
acid transporter URATv1 reduces NO production via 
dephosphorylation of eNOS, causing endothelial dysfunction. 
 
2) Soluble uric acid and cardiovascular diseases. 
 In humans, 90% of uric acid filtered at the glomeruli 
is reabsorbed in the renal tubules. Uric acid is reabsorbed 
Table 2. Clinical questions and recommendations for hyperuricemia with CKD, hypertension and heart 
failure 
CQ (A): Can urate lowering agents be recommended in patients with hyperuricemia and 
kidney injury over non-medication?  
Recommendation 
The use of urate lowering agents to retard the decline in kidney function is conditionally 
recommended in patients with hyperuricemia and kidney injury. 
  
CQ (B):Can urate lowering agents be recommended for hypertensive patients with 
hyperuricemia over non-medication treatment?  
Recommendation 
The use of urate lowering agents to improve life prognosis and reduce the risk of 
cardiovascular disease cannot be conditionally recommended for hypertensive patients 
with hyperuricemia 
  
CQ (C): Can urate lowering agents be recommended for patients with heart failure and 
hyperuricemia over non-medication treatment?  
Recommendation 
The use of urate lowering agents to improve life prognosis and reduce the risk of 
cardiovascular disease cannot be conditionally recommended for patients with heart 





Journal of Biomedicine and Translational Research, 6 (3) 2020, 101-109  
by the urate transporter 1 (URAT1) localized on the 
apical side of proximal tubular cells,1 whereas it exits the 
cells via voltage-driven urate transporter 1 (URATv1) 
located at the basolateral side.1 Recent experimental 
studies 35 have shown that uric acid transporters are 
expressed not only in renal tubular cells but also in other 
types of cells, and that four uric acid transporters 
URATv1, MCT9, ABCG2 and MRP4 are commonly 
expressed in various organs. URATv1 and MCT9 belong 
to the influx transporter that reabsorb uric acid, whereas 
ABCG2 and MRP4 belong to the efflux transporter that 
secrete uric acid.   
 Mishima et al. demonstrated that in HUVECs, uric 
acid reduced NO production through eNOS 
dephosphorylation and that NO production were restored 
by urate transporter inhibitors,36 suggesting that uric acid 
absorbed into endothelial cells causes inflammation, 
oxidative stress and dephosphorylation of eNOS [Figure 
2].  
 Mouse atrial myocytes express at least four UATs: 
URATv1/GLUT9, ABCG2, MRP4 and MCT9.37 Uric 
acid could stabilize Kv1.5 channel proteins in mouse 
atrial myocytes (HL-1 cells) (Figure 3), resulting in an 
increase of ultra-rapid delayed-rectifier current (IKur) and 
shortening of the atrial action potential through UATs. 
Inhibition of uric acid-influx UATs by benzbromarone 
attenuated UA-induced enhancement of Kv1.5 protein 
expression. Inhibition of uric acid-efflux transporter 
ABCG2 accelerated UA-induced enhancement of Kv1.5 
protein expression. Intracellular uric acid damaged the 
cells via an increase of oxidative stress and activation of 
the ERK1/2/Akt pathway together with phosphorylation 
of HSF-1 and HSP70.37,38 This effect was oxidative 
stress-dependent, since the enhancement of Kv1.5 
protein expression by uric acid was reversed by the 
antioxidant N-acetylcysteine and the NADPH-oxidase 
inhibitor apocynin. This process involved the ERK1/2 
pathway as part of the downstream signaling of urate-
derived ROS, which was in consistent with the findings 
of other studies39. An antioxidant may be a novel 
therapeutic approach against AF in hyperuricemic 
patients. 
Figure 3. Intracellular uric acid causes the electrical 
remodeling of atrial myocytes 
Accumulation of intracellular uric acid through UAT 
(URATv1/MCT9) induces nicotinamide adenine dinucleotide 
phosphate (NADPH)-oxidase-dependent reactive oxygen 
species (ROS) production to increase Kv1.5 through 
Akt/ERK/HSF-1/HSP70 pathway. AKT, protein kinase B; 
HSF-1-S326, Ser 326 at heat shock factor 1; Hsp70, heat shock 
protein 70; URATv1/MCT9, influx uric acid transporters. 
ABCG2/MRP4, efflux uric acid transporters 
 
3) Xanthine oxidase and cardiovascular diseases 
 XOR is a central player in the formation of uric acid. 
XOR is composed of XDH and XO. XO is generated 
from XDH by its protein modification and catalyses the 
last few steps of the reactions that convert hypoxanthine 
to xanthine, and xanthine to uric acid. These reactions 
yield hydrogen peroxide and reactive oxygen species 
(ROS).40 A high activity of XO creates pro-oxidative 
condition by generating O2
− which results in a decrease 
in nitric oxide expression, and endothelial dysfunction. 
Although XOR is highly active in the liver and small 
intestine, it also exists both in the cytoplasm and on the 
surface of endothelial cells. Recently, XOR was found to 
exist in human plasma. This circulating XOR is believed 
to be released from XO-rich organs such as liver. It 
binds glycosaminoglycans on the surface of endothelial 
cells and may be subsequently endocytosed [Figure 3].41 
The endothelial dysfunction has further consequences 
including reduced vascular elasticity, platelet 
aggregation, increased proliferation of smooth muscle 
cells, and fibrotic remodelling.42  
 A study using mice fed with Western diet showed the 
high SUA level was followed by an increase in XO 
activity. The mice developed cardiac hypertrophy, 
oxidative stress in myocardium, interstitial fibrosis and 
impaired diastolic relaxation, which were improved after 
allopurinol therapy.43 An in-vivo study in dogs assessed 
the effect of allopurinol on the progression of atrial 
vulnerability. Allopurinol was able to suppress AF by 
inhibiting both electrical and structural remodelling of 
the atrium, suggesting the role of XO in enhancement of 
atrial vulnerability.44  
 
Uric Acid-Induced Modification of Neurohumoral 
Factors in The Cardiovascular System  
1) Uric Acid and Insulin Resistance 
 Insulin resistance is the core of pathophysiology in 
metabolic syndrome and is linked to several diseases 
including diabetes mellitus, stroke, and coronary artery 
disease.45 The increase of SUA is accompanied by 
increased prevalence of the metabolic syndrome.46 Choi 
et al 47 reported that elevation of fasting plasma insulin 
level correlates with elevation of SUA. Hyperinsulinemia 
due to insulin resistance enhanced both renal 
reabsorption of uric acid via activation of URAT1 and 
hepatic production of uric acid.  
 Hyperuricemia may in turn, cause insulin resistance. 
Insulin stimulates release of NO from endothelial cells, 
which causes vasodilation and aids delivery of glucose to 
the skeletal muscle. Uric acid reduces endothelial NO via 
several mechanisms, including inhibition of L-arginine 
uptake,48 stimulation of L-arginine degradation49 and 
chelating NO,50 leading to suppression of vasodilation 
and glucose delivery.  
 Uric acid may also induce insulin resistance via its 
effects on adipocytes. Uric acid enters adipocytes via 
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activation of NADPH oxidase, generating oxidized 
lipids and inflammatory mediators such as monocyte 
chemoattractant protein-1 (MCP-1)51,52 These events 
lead to inflammation, insulin resistance, and a decrease 
in adiponectin synthesis.51 In the hyperuricemic mouse, 
allopurinol attenuates the inflammatory response in the 
visceral fat, reduces the expression of inflammatory 
cytokines, and enhances circulating levels of 
adiponectin.52 Likewise, administration of allopurinol or 
benzbromarone in the fructose-fed rat resulted in less 
insulin resistance and decreases the leptin level in the 
visceral fat.53  
 
2) Uric Acid and the Renin-Angiotensin System 
(RAS) 
 Hyperuricemia has been reported to activate the 
systemic RAS in the kidney. Uric acid increases renin 
expression, and studies in adult patients with essential 
hypertension54 and hyperuricemic children 55 have also 
found an association of the plasma renin activity (PRA) 
and SUA. SUA level also correlated with urinary 
excretion of aldosterone in healthy men. Renal biopsy 
from rats demonstrated a correlation between SUA and 
the number of renin positive juxtaglomerular cells.56 
Hyperuricemic rats exhibited increased juxtaglomerular 
renin and decreased macular densa neuronal NOS.57  
 Uric acid stimulates formation of angiotensin II in 
vascular endothelial cells via activation of the 
inflammatory pathway. Cellular uptake of uric acid into 
cells via URAT1, induces oxidative stress, activation of 
mitogen activated protein kinases, and the nuclear factor 
kappa b and APO-1.58 These processes lead to release of 
vasoconstrictors, including thromboxane, endothelin-1 
and angiotensin II.59 Uric acid is an antioxidant in the 
extracellular environment, but it has direct prooxidative 
effects once it gains entry into cells such as endothelial 
cells, adipocytes and vascular smooth muscle cells. This 
is followed by activation of the local RAS, angiotensin 
II type 1 and type 2 receptor expression, and the 
induction of senescence and apoptosis of endothelial 
cells.59  
 
Rationality of Pharmacological Treatment of 
Asymptomatic Hyperuricemia  
 Is asymptomatic hyperuricemia should be treated in 
patients with cardio-renovascular disease? There are 
different recommendations for pharmacological 
treatment of asymptomatic hyperuricemic patients 
between Western countries and Asian country Japan. 
The European and American guidelines60 do not 
recommend use of uric acid lowering agents (ULAs) for 
asymptomatic hyperuricemia to prevent gout, renal 
dysfunction and cardiovascular events. In contrast, 
Japanese guideline recommend use of ULAs for 
asymptomatic hyperuricemia. Medicare system in Japan 
cover the medical expense in treatment with ULAs of 
asymptomatic hyperuricemia. Therefore, it is easy to 
conduct the clinical trials to examine whether 
pharmacological treatment of hyperuricemia could be 
reasonable have been conducted. FEATHER study61 
reported that the treatment with xanthine oxidase 
inhibitor febuxostat significantly reduce the newly onset 
of gout in asymptomatic hyperuricemia with CKD 
compared to placebo, demonstrating the rationality of 
their pharmacological treatment of asymptomatic 
hyperuricemia in order to prevent gout.  
 Japanese guideline 2nd edition62 states that ULAs may 
be considered when patients have renal dysfunction, 
lifestyle related diseases or cardiovascular diseases and 
their SUA is > 8 mg/dl. The Japanese Guideline for the 
Treatment of Hyperuricemia and Gout 3rd edition1 was 
developed to clarify the rationality of pharmacological 
treatment in asymptomatic hyperuricemia in order to 
protect kidney disease or CVD according to GRADE 
approach. In order to make a recommendation to clinical 
questions (CQs) in this guideline, after setting the key 
clinical issues on hyperuricemia and gout, CQs together 
with advantage and disadvantage outcomes have been 
selected. Using systematic reviews on reports related to 
outcome of each CQs, the bias risk of each evidence has 
been estimated.  
 Taken together with the certainty in body of evidence, 
patients’ opinions and medical economics, the 
recommendation for each clinical question has been 
determined. As shown in Table 2, the recommendations 
have 3 elements: direction of recommendation, strength 
of the recommendation and strength (certainty) of 
evidence, and recommendations were expressed using 
combinations of these. The direction of recommendation 
refers to whether the recommendation will be 
implemented. Strength of recommendation refers to 
whether the recommendation is strong or weak, while the 
strength of evidence corresponds to one of A (strong), B 
(moderate), C (weak/low), or D (very weak/low) 
according to the GRADE approach. As referred to CQ 
(A) in Table 2, ULAs improved the renal function and 
suppressed the end-stage renal failure in CKD patients, 
although there was not any significant difference in 
adverse effects between ULAs treatment and placebo 
groups, indicating that the benefit of treatment with 
ULAs is much greater than the harm. Thus, in order to 
prevent renal failure, ULAs are partially recommended 
for use in hyperuricemic patients with CKD. There is not 
enough evidence that ULAs improve the total mortality 
or cardiovascular mortality in patients with both 
hypertension (CQ (B)) and chronic heart failure (CQ 
(C)), although there was no difference in adverse effects 
between ULAs treatment and placebo groups. Thus, in 
order to prevent CVD or improve prognosis, ULAs are 
not partially recommended for use in either 
hyperuricemic patients with hypertension or 
hyperuricemic patients with heart failure. Recently, 
FREED study63 reported that febuxostat significantly 
improved the primary composite endpoint of cardio-
renovascular events in hypertension, diabetes and 
cerebro-cardiovascular disease in patients with 
hyperuricemia. This improvement was attributable to 
improvement of renal function indicating that 
improvement in renal function restores cardiac function 
(cardio-renal continuum). Thus, in order to reduce 
mortality in cardio-renovascular disease patients, ULAs 
could be used, when patients agree.  
 Japanese Medicare system covers the medical 
expense for treatment with ULAs in patients with 
asymptomatic hyperuricemia with being different from 
western countries. Taken together with the evidences 
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could not only reduce the onset of gout and CKD, but 
also decrease the onset of CVDs through improvement 
of cardio-renal continuum, thus, it is strongly 
recommended that like Japan, Asian and western country 
may consider the rationality of pharmacological 
treatment of asymptomatic hyperuricemia to reduce both 
gout and reno-cardiovascular diseases. 
 
CONCLUSION 
 Hyperuricemia together with XO can induce 
inflammation, endothelial dysfunction and remodeling 
of the cardiovascular systems through UATs, free radical 
or crystal induced NLRP3 inflammasome, which play a 
pivotal role in development of CVDs as a risk. Several 
lines of evidence report in the Japanese guideline 
attaches importance of the cardio-renal interaction for 
treatment of asymptomatic hyperuricemia patients. 
Thus, this review demonstrates the rationality of 
pharmacological treatment of asymptomatic 
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